Introduction
============

Beside the well-characterized 17β-estradiol (E~2~) that is considered as the active estrogen during the estrous cycle, estriol (E~3~) and also estetrol (E~4~) are synthesized during pregnancy, but their physiological roles are essentially unknown. It is hypothesized that these two weaker estrogens could interfere with E~2~ and attenuate its actions in estrogen-sensitive tissues. Indeed, E~3~ has an affinity for estrogen receptor (ER) and a biological potency that are both tenfold lower than that of E~2~. When administered with E~2~, E~3~ can act as an antiestrogen and partially interfere with E~2~-dependent transcription (Melamed *et al*, [@b34]). E~4~ is viewed as a weaker estrogen, with affinity and potency 100-fold lower than those of E~2~ (Holinka & Gurpide, [@b22]), but its antagonistic actions are poorly defined. E~4~ shares with E~2~ and E~3~ several estrogenic activities such as uterine growth and epithelial proliferation (Holinka & Gurpide, [@b22]), prevention of bone demineralization (Coelingh Bennink *et al*, [@b14]), inhibition of ovulation (Coelingh Bennink *et al*, [@b15]), and prevention of hot flushes (Holinka *et al*, [@b23]).

E~4~ appears to be produced exclusively by the human fetal liver (Hagen *et al*, [@b19]). E~4~ also differs from E~2~ by having a long plasma half-life (about 28 h) (Visser & Coelingh Bennink, [@b49]), and it neither stimulates the production of nor binds to sex hormone binding globulin (SHBG) (Hammond *et al*, [@b20]). Because of these characteristics, E~4~ was evaluated, in combination with a progestin, as a new oral contraceptive in a phase II clinical trial (I. Duijkers I., C. Klipping C., Y. Zimmerman, L. Petit, M. Mawet, J-M. Foidart, H. Coelingh Bennink, in preparation). Very interestingly, E~4~ (up to 20 mg/day) did not elicit changes in circulating hepatic factors and thus might not increase thrombo-embolic events, which are undesirable effects of estrogen pharmaceuticals containing E~2~ or ethinyl-estradiol (EE) (C. Kluft Cornelis, Y. Zimmerman, M. Mawet Marie, C. Klipping, I. Duijkers Ingrid, L. Petit, J. Neuteboom, J-M Foidart, H. Coelingh Bennink, in preparation). Unfortunately, as previously reported (Valera *et al*, [@b46]), the impact of estrogen on hepatic factors is species dependent, which precludes the use of mice as an animal model to elucidate these mechanisms.

The physiological responses to estrogenic compounds are initiated by their binding to the estrogen receptors (ER), ERα and ERβ. E~4~ binds ERα with a modest preference over ERβ (Visser *et al*, [@b48]). ER mediates its transcriptional activity after ligand binding inducing an ordered sequence of interactions between two activation functions (AF), AF-1 and AF-2, and coactivators such as the steroid receptor coactivator (SRC) 3, a member of the p160 subfamily (McKenna & O\'Malley, [@b33]; Metivier *et al*, [@b36]; Smith & O\'Malley, [@b41]). In addition, estrogens can act through a distinctly different pathway by inducing rapid extra-nuclear activity via the activation of a pool of ERs localized at the plasma membrane, a process termed membrane-initiated steroid signaling (MISS) (Ascenzi *et al*, [@b6]; Wu *et al*, [@b52]). Although ERα MISS effects were initially also called 'non-genomic' effects, they can modulate ERα-dependent transcriptional activity in cultured cell models *in vitro* (La Rosa *et al*, [@b29]). However, thanks to a unique mouse model targeted for the ERα palmitoylation site membrane, we recently demonstrated a very contrasted involvement of MISS-mediated E~2~ action in two different tissues: the uterus in which the E~2~ response depends on ERα nuclear action and the arteries involving exclusively MISS of ERα to mediate E~2~ response (Abot *et al*, [@b1]; Adlanmerini *et al*, [@b4]).

The aim of this study was to analyze the molecular action of E~4~ using structural, *in vitro* and *in vivo* models. First, experiments were conducted to analyze the binding of E~4~ to ERα-LBD and to investigate the role of the two activation functions AF-1 and AF-2 in the transcriptional activity of E~4~ in comparison to E~2~. Second, we studied the impact of acute E~4~ treatment on gene expression and epithelial cell proliferation in uterus, which involved primarily genomic/transcriptional actions of ERα but not ERα MISS (Abot *et al*, [@b1]; Adlanmerini *et al*, [@b4]). Third, we analyzed the effect of chronic E~4~ treatment on fatty streak deposit formation at the aortic root of ovariectomized LDLr^−/−^ (Low Density Lipoprotein receptor) mice fed with an hypercholesterolemic diet. Fourth, we evaluated the effect of E~4~ on endothelial functions recognized to be dependent on MISS ERα signaling, namely acceleration of endothelial healing and activation of endothelial NO synthase (Brouchet *et al*, [@b11]; Toutain *et al*, [@b44]; Chambliss *et al*, [@b12]; Wu *et al*, [@b52]; Adlanmerini *et al*, [@b4]). Finally, MISS of ERα versus nuclear action after E~4~ stimulation was analyzed in the breast cancer cell line, MCF-7. The present studies reveal that high doses of E~4~ stimulated nuclear ERα actions in the uterus but E~4~ failed to promote MISS in the endothelium, and a similar profile of activation was also observed in MCF-7 cells. This profile of ERα activation indicates that E~4~ is a selective ER modulator which could have medical applications that should now be considered further, in particular in light its lesser hepatic effects in women, which could potentially reduce venous thrombo-embolic risk.

Results
=======

Comparison of the ERα LBD structure, of the coactivator interaction, and of the solubility/orientation in phospholipids bilayer model membranes after E~2~ and E~4~ binding
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In order to gain insight into the molecular mechanism of action of E~4,~ we first compared the crystal structures of ERα LBD complexed with E~3~ (3Q95) or E~4~ (3L03) to the published E~2~-ERα structure (1ERE) and we found all of them very similar in their overall conformation (Fig [1](#fig01){ref-type="fig"}A and B). In addition, the two ligands are perfectly superimposable and interact equally with residues within the ligand-binding pocket (Fig [1](#fig01){ref-type="fig"}B). The only significant difference between these structures is the altered orientation of helix 12 and the loop between helices 11 and 12 relative to that in the E~2~-ERα LBD complex (Fig [1](#fig01){ref-type="fig"}C). However, this small difference does not prevent binding of the GRIP peptide to the E~3~- or E~4~-ERαLBD to stabilize an agonist conformation (Fig [1](#fig01){ref-type="fig"}C). Using competitive radiometric binding assays, we found, as reported previously (Visser *et al*, [@b48]), that E~4~ and E~3~ bind to ERα with less affinity than E~2~ and with a small preference over ERβ (Supplementary Table S1). The binding affinity of the steroid receptor coactivator SRC3 to complexes of ligands with the ERα ligand-binding domain can be quantified by a time-resolved fluorescence resonance transfer assay (tr-FRET) (Jeyakumar *et al*, [@b26]). In this assay, E~3-~ERα and E~2-~ERα have essentially identical affinities for SRC3, and the affinity of E~4~-ERα, while half that of E~2~-ERα, is still in the low nanomolar range (Supplementary Fig S1 and Supplementary Table S2). Thus, as a hormonal ligand, while E~4~ has considerably lower binding affinity for ERα than E~2~, it forms a complex with this receptor that binds to a key coactivator protein, SRC3, almost as well as does the complex with E~2~.

![Structure of E~2~, E~3~ and E~4~ and their respective complexed structure with ERα ligand binding domain\
A Chemical structures of E~2~, E~3~, and E~4~.\
B, C Structure of ERαLBD complexed with E~2~ (blue), E~3~ (red), or E~4~ (green). Shown are ribbon diagrams of the ERαLBD monomer. Ligand-binding site (B), shown in ball-and-stick rendering of the ligands along with their interacting residues. Hydrogen bonds are shown as dotted lines. Ligand-binding domain (C) and peptide fragment of the GRIP1 coactivator protein in complex with E~3~ or E~4~ only (darker red and darker green). Ligand is represented as a space-filled model. Position of the helix 12 is indicated by an arrow.](emmm0006-1328-f1){#fig01}

As a consequence of its two extra hydroxyl groups, one might expect E~4~ to be less hydrophobic than E~2~ (Fig [1](#fig01){ref-type="fig"}A); in fact, its calculated octanol--water partition coefficient (ClogP^*o/w*^) is 2.62 versus 3.78 for E~2~. Thus, we hypothesized that E~4~ would less readily partition into the plasma membrane than E~2~ (Yamamoto & Liljestrand, [@b53]). However, we found a similar solubility for E~2~ (˜4 mol%) and E~4~ (˜2 mol%) into palmitoyl-oleoyl-phosphatidylcholine (POPC) liposomes using nuclear magnetic resonance, indicating that their uptake is equivalent (Supplementary Fig S2A). In addition, contrary to what is described by Scheidt *et al* ([@b39]), we found that E~2~ is in an equilibrium between two orientations in the bilayer (phenol at the lipid--water interface versus phenol within the hydrophobic core), whereas the phenol of E~4~ is oriented more predominantly toward the lipid--water interface (Supplementary Fig S2B). While unexpected, this behavior of E~4~ may be a consequence of an efficient intramolecular network of hydrogen bonds, operating among the three OH groups in the D-ring that in some way effectively suppresses their polar nature, thus allowing the D-ring to reside more comfortably in the hydrophobic core of the bilayer. In contrast, the lone 17β-OH in E~2~, which would be fully surrounded by a hydrophobic environment when in the core of the bilayer, more effectively competes with the phenolic OH for access to the aqueous interface, resulting in the two orientations of this ligand.

Respective roles of ERα AF-1 and AF-2 in the transcription activity induced by E~4~
-----------------------------------------------------------------------------------

We then evaluated the ability of E~4~ to induce transcriptional activity of an estrogen-sensitive reporter gene (ERE-TK-Luc) in transient transfection assays *in vitro*. The dose--response effect of E~4~ was compared with that of E~2~ in HeLa cells transfected with an expression vector encoding the full-length ERα. E~4~ displayed a marked rightward dose--response shift compared to E~2~, requiring at least 100-fold higher hormone concentration to achieve half-maximal stimulation of the reporter gene (Fig [2](#fig02){ref-type="fig"}A), consistent with its lower ERα binding affinity.

![E~4~ induces ERE transcriptional activity in a cellular context-dependent manner *in vitro* in a manner similar to that of E~2~\
A, B HeLa (A, B) and HepG2 (B) cells were transiently transfected with the ERE-TK-Luc reporter constructs in the presence of pCR-ERα, pCR-ERαΔ79, pCR-ERαAF-1^0^, or empty pCR vector. Cells were treated with indicated dose of E~2~ and E~4~ or vehicle (Ctrl) for 24 h. Normalized luciferase activities were expressed as fold increase above values measured with empty pCR and vehicle. Data correspond to the mean values ± SEM of at least three separate transfection experiments.](emmm0006-1328-f2){#fig02}

E~4~ modulation of activation function AF-1 and AF-2 of ERα was then evaluated in HepG2 and HeLa cell lines (Fig [2](#fig02){ref-type="fig"}B). Whereas AF-1 is the dominant AF involved in ERα transcriptional activity in HepG2 cells, HeLa cells mediate ERα signaling mainly through AF-2 (Merot *et al*, [@b35]). Furthermore, cell permissiveness to either ERα AFs was determined by comparing the transcriptional activity of the full-length ERα with those of ERαΔ79 (deletion of only AF-1 box 1) and ERαAF-1^0^ (additional deletion of AF-1 box 2/3). In HepG2 cells, as is the case for E~2~, the main region involved in E~4~-induced ERα transcriptional activity is the AF-1 box 1 (ERαΔ79 versus ERα, 65% decrease of the total activity, Fig [2](#fig02){ref-type="fig"}B), the remaining activity depending upon the AF-1 box 2/3, as expected (Huet *et al*, [@b25]). In contrast, the AF-1 box 1 (ERαΔ79 versus ERα) represents \< 20% of the E~2~- or E~4~-induced ERα transcriptional potency in HeLa cells. These results show that a high concentration of E~4~ is able to activate gene transcription through ERα via the classical ERE mechanism. In addition, as previously described for E~2~, both AFs are involved in this action in a cell type-dependent manner.

Impact of acute E~4~ treatment on uterine gene expression and epithelial proliferation
--------------------------------------------------------------------------------------

We then assessed the transcriptional activity of E~4~ *in vivo* on the uterus in C57Bl/6J mice. We selected a set of genes known to be regulated by E~2~ in this tissue (Hewitt *et al*, [@b21]; Watanabe *et al*, [@b50]; Abot *et al*, [@b1]) and evaluated their expression profile in ovariectomized mice after an acute dose of each estrogen alone. Dose--response studies (E~2~: 8, 30, 80, and 200 μg/kg and E~4~: 8, 30, 80, 200, 600 μg/kg, or 1 and 10 mg/kg) indicated that most of the regulated genes reached their maximum level of induction at the lowest dose of E~2~, that is, 8 μg/kg (Table [1](#tbl1){ref-type="table"}), and of repression, between 8 and 30 μg/kg of E~2~ (Table [2](#tbl2){ref-type="table"}). In most cases, compared to E~2~, E~4~ required a 100-fold higher dose (i.e.*,* 1 mg/kg) to optimally activate the transcription of target genes (Table [1](#tbl1){ref-type="table"}), although 7 of the 23 studied genes were activated at lower levels of E~4~. Concerning down-regulated genes, a dose of 80 μg/kg of E~4~ was sufficient to induce the maximal action (Table [2](#tbl2){ref-type="table"}). Plasma analysis showed that a subcutaneous injection of 1 mg/kg E~4~ resulted in an E~4~ plasma concentration of 16,100 pg/ml after 6 h of treatment, a value close to that found for E~4~ in human fetal plasma (18,630 pg/ml). All E~2~ (8 μg/kg) target genes in the uterus were also regulated (at least twofold) by E~4~ (1 mg/kg) (Fig [3](#fig03){ref-type="fig"}A, Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}) and have been distributed into three groups, according to the response to E~2~ versus E~4~ (Fig [3](#fig03){ref-type="fig"}B). Cluster 1 represents genes similarly regulated by E~2~ at 8 μg/kg and E~4~ at 1 mg/kg doses; cluster 2 genes were found to be less regulated by E~4~ than by E~2~, and cluster 3 genes more regulated by E~4~ than by E~2~ at these doses. Yellow highlight is used to designate gene expression regulation by E~2~ that is greater than by E~4~ (Fig [3](#fig03){ref-type="fig"}B, middle), whereas gene expression that is more regulated by the same dose of E~4~, is highlighted in blue (Fig [3](#fig03){ref-type="fig"}B, bottom). It is noteworthy that this latter category involved mainly down-regulated genes.

###### 

Seven-week-old ovariectomized C57Bl/6J mice were subcutaneously injected with vehicle (Ctrl, castor oil), 17β-estradiol (E~2~, 1, 8, 30, 80, 200 μg/kg) or estetrol (E~4~, 1, 8, 30, 80, 200 μg/kg, or 1 and 10 mg/kg) and were euthanized 6 h after treatment. mRNA levels of a set of genes from uterus that were up-regulated at least twofold by E~2~ administration relative to placebo were measured by quantitative PCR and normalized to Hprt1 expression

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GOI       Dose E~2~ (µg/kg)   Dose E~4~ (µg/kg)                                                                                                                                                                    
  --------- ------------------- ------------------- ----------------- ----------------- ----------------- ---------------- ----------------- ----------------- ----------------- ----------------- ----------------- -----------------
  ramp3     0.81 ± 0.06         30.84 ± 1.48\       21.71 ± 0.45\     22.33 ± 0.42\     29.04 ± 3.11\     0.91 ± 0.10      2.01 ± 0.36\      10.09 ± 0.13\     16.22 ± 0.21\     23.20 ± 0.85\     29.87 ± 1.17\     27.75 ± 2.34\
                                *P *\< 0.0001       *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0005    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  gadd45g   1.08 ± 0.15         19.87 ± 0.58\       9.05 ± 0.31\      6.89 ± 0.44\      11.96 ± 2.59\     0.91 ± 0.19      2.31 ± 0.49\      5.49 ± 0.89\      6.52 ± 0.89\      6.84 ± 0.62\      10.96 ± 0.42\     9.49 ± 0.69\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0002    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  mad2l1    0.83 ± 0.06         19.63 ± 0.33\       7.69 ± 0.54\      5.54 ± 0.56\      7.59 ± 0.56\      0.79 ± 0.16      0.46 ± 0.17\      1.42 ± 0.10\      1.82 ± 0.23\      2.80 ± 0.38\      11.03 ± 2.03\     15.52 ± 0.46\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0014    *P *=* *0.0058    *P *=* *0.0009    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  inhbb     0.78 ± 0.06         18.13 ± 1.62\       8.93 ± 0.36\      7.86 ± 0.41\      10.45 ± 1.29\     0.90 ± 0.03      1.44 ± 0.08\      5.36 ± 0.23\      5.76 ± 0.15\      6.81 ± 0.24\      10.55 ± 0.58\     11.44 ± 0.99\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0024    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  fam65b    0.81 ± 0.04         12.92 ± 1.07\       10.09 ± 0.33\     8.03 ± 0.97\      9.53 ± 0.86\      0.97 ± 0.11      1.65 ± 0.05\      4.42 ± 0.58\      6.53 ± 0.31\      8.08 ± 1.01\      9.85 ± 0.53\      10.77 ± 1.31\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  fos       0.97 ± 0.14         12.36 ± 2.19\       1.42 ± 0.13       1.29 ± 0.21       3.60 ± 1.39\      0.81 ± 0.24      0.99 ± 0.22       1.64 ± 0.31       1.23 ± 0.10       3.59 ± 1.37\      6.26 ± 1.61\      2.91 ± 0.54\
                                *P *\<* *0.0001                                         *P *=* *0.075                                                                            *P *=* *0.0182    *P *=* *0.0005    *P *=* *0.0001

  aldh1a2   1.08 ± 0.07         9.94 ± 0.68\        9.29 ± 0.36\      9.12 ± 0.75\      8.61 ± 0.45\      1.25 ± 0.06\     1.07 ± 0.13       5.38 ± 0.38\      8.33 ± 0.36\      7.62 ± 0.45\      7.91 ± 0.39\      7.22 ± 0.45\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *=* *0.0241                     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  p21       1.01 ± 0.06         9.17 ± 0.66\        9.37 ± 0.34\      6.49 ± 0.54\      8.62 ± 1.04\      1.01 ± 0.07      1.83 ± 0.27\      5.57 ± 0.37\      6.09 ± 0.60\      6.89 ± 0.38\      7.80 ± 0.67\      6.33 ± 0.82\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0002    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  aars      0.98 ± 0.05         6.95 ± 0.30\        10.50 ± 0.05\     9.00 ± 0.75\      9.24 ± 1.06\      1.04 ± 0.03      1.33 ± 0.10\      7.12 ± 0.04\      7.03 ± 0.50\      7.84 ± 0.73\      7.94 ± 0.77\      7.77 ± 0.62\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0062    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  lcn2      1.04 ± 0.11         6.68 ± 0.48\        4.93 ± 0.51\      5.61 ± 0.96\      9.42 ± 1.18\      0.98 ± 0.02      0.81 ± 0.03       5.86 ± 0.56\      8.12 ± 0.69\      10.21 ± 0.90\     9.04 ± 1.36\      6.12 ± 0.42\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                      *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  errfi1    1.06 ± 0.14         6.62 ± 0.84\        3.41 ± 0.18\      3.13 ± 0.12\      4.25 ± 0.96\      1.16 ± 0.14      1.94 ± 0.35\      2.86 ± 0.56\      2.04 ± 0.25\      2.45 ± 0.32\      3.10 ± 0.27\      2.30 ± 0.16\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0002    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  sprr2f    0.89 ± 0.12         6.25 ± 1.36\        1.37 ± 0.09       4.48 ± 1.35\      4.87 ± 1.43\      0.98 ± 0.26      0.41 ± 0.21\      2.36 ± 0.55\      3.02 ± 0.18\      3.88 ± 0.80\      10.70 ± 1.49\     10.01 ± 0.75\
                                *P *\<* *0.0001                       *P *=* *0.0002    *P *=* *0.0007                     *P *=* *0.0129    *P *=* *0.0007    *P *\<* *0.0001   *P *=* *0.0001    *P *\<* *0.0001   *P *\<* *0.0001

  rasd1     1.13 ± 0.07         5.97 ± 0.35\        4.18 ± 0.19\      3.28 ± 0.23\      3.47 ± 0.19\      1.06 ± 0.11      1.42 ± 0.22\      1.61 ± 0.32\      1.18 ± 0.19       1.42 ± 0.37       2.49 ± 0.23\      3.18 ± 0.13\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0134    *P *=* *0.0035                                        *P *\<* *0.0001   *P *\<* *0.0001

  vegfa     0.86 ± 0.10         5.04 ± 0.51\        4.23 ± 0.28\      3.06 ± 0.37\      3.61 ± 0.29\      0.97 ± 0.04      1.11 ± 0.09       2.13 ± 0.09\      1.43 ± 0.12\      1.63 ± 0.14\      2.91 ± 0.32\      3.60 ± 0.51\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                      *P *\<* *0.0001   *P *=* *0.0037    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  cebpb     0.92 ± 0.03         4.54 ± 0.23\        2.82 ± 0.19\      2.37 ± 0.29\      2.72 ± 0.08\      1.21 ± 0.04      0.86 ± 0.10       1.54 ± 0.10\      1.08 ± 0.09       1.20 ± 0.13       1.59 ± 0.11\      1.87 ± 0.08\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                      *P *=* *0.0011                                        *P *\<* *0.0001   *P *\<* *0.0001

  psat1     1.18 ± 0.08         4.31 ± 0.23\        8.98 ± 0.45\      9.95 ± 0.70\      8.26 ± 1.22\      1.15 ± 0.09      0.81 ± 0.05       5.09 ± 0.38\      5.49 ± 0.45\      4.96 ± 0.65\      5.07 ± 0.51\      5.30 ± 0.70\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                      *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  gadd45a   1.02 ± 0.03         3.70 ± 0.40\        4.88 ± 0.35\      4.09 ± 0.64\      3.77 ± 0.56\      0.81 ± 0.05\     1.21 ± 0.12       3.09 ± 0.20\      2.22 ± 0.24\      2.54 ± 0.47\      3.33 ± 0.40\      3.16 ± 0.21\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *=* *0.0436                     *P *\<* *0.0001   *P *\<* *0.0001   *P *=* *0.0003    *P *\<* *0.0001   *P *\<* *0.0001

  hspa5     1.04 ± 0.01         3.28 ± 0.19\        3.03 ± 0.18\      3.71 ± 0.31\      4.95 ± 0.84\      1.01 ± 0.01      1.18 ± 0.04       2.23 ± 0.15\      4.90 ± 0.32\      5.17 ± 0.48\      5.58 ± 0.54\      5.64 ± 0.35\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                      *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  igf1      1.07 ± 0.03         3.27 ± 0.15\        2.82 ± 0.08\      3.52 ± 0.23\      3.67 ± 0.30\      1.11 ± 0.09      1.07 ± 0.08       3.18 ± 0.15\      4.19 ± 0.24\      3.72 ± 0.18\      4.01 ± 0.18\      5.23 ± 0.89\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                      *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  cars      1.07 ± 0.11         3.16 ± 0.04\        3.55 ± 0.27\      3.73 ± 0.37\      4.26 ± 0.32\      0.96 ± 0.10      1.06 ± 0.08       3.19 ± 0.09\      3.62 ± 0.35\      3.47 ± 0.23\      4.27 ± 0.54\      3.96 ± 0.37\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                      *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  cyr61     0.91 ± 0.12         2.73 ± 0.16\        0.96 ± 0.07       1.11 ± 0.18       2.08 ± 0.81\      0.73 ± 0.19      0.56 ± 0.07\      0.75 ± 0.12       0.94 ± 0.13       2.65 ± 0.92\      4.23 ± 0.57\      3.08 ± 0.15\
                                *P *\<* *0.0001                                         *P *=* *0.0560                     *P *=* *0.0442                                        *P *=* *0.0245    *P *\<* *0.0001   *P *\<* *0.0001

  dio2      0.79 ± 0.06         2.49 ± 0.47\        2.05 ± 0.07\      3.67 ± 0.33\      4.60 ± 0.71\      1.03 ± 0.10      0.73 ± 0.07       1.33 ± 0.08\      2.68 ± 0.21\      4.60 ± 0.40\      6.30 ± 0.66\      5.12 ± 0.38\
                                *P *=* *0.0002      *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                      *P *=* *0.0036    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  pgr       0.87 ± 0.04         2.47 ± 0.17\        1.80 ± 0.03\      1.67 ± 0.09\      1.90 ± 0.07\      0.88 ± 0.05      1.25 ± 0.04\      1.58 ± 0.06\      1.55 ± 0.09\      1.74 ± 0.11\      2.31 ± 0.13\      2.20 ± 0.09\
                                *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0163    *P *\<* *0.0001   *P *=* *0.0002    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results were expressed as mean ± SEM (*n* = 4--8 mice/group). Significance of the observed effects was evaluated using Student\'s *t*-test. Gray highlight represents the maximum of regulation

###### 

Seven-week-old ovariectomized C57Bl/6J mice were subcutaneously injected with vehicle (Ctrl, castor oil), 17β-estradiol (E~2~, 1, 8, 30, 80, 200 μg/kg) or estetrol (E~4~, 1, 8, 30, 80, 200 μg/kg, or 1 and 10 mg/kg) and were euthanized 6 h after treatment. mRNA levels of a set of genes from uterus that were down-regulated at least twofold by E~2~ administration relative to placebo were measured by quantitative PCR and normalized to Hprt1 expression

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GOI      Dose E~2~ (µg/kg)   Dose E~4~ (µg/kg)                                                                                                                                                                   
  -------- ------------------- ------------------- ----------------- ----------------- ----------------- ---------------- ---------------- ----------------- ----------------- ----------------- ----------------- -----------------
  esr2     0.92 ± 0.09         0.50 ± 0.04\        0.32 ± 0.05\      0.34 ± 0.04\      0.56 ± 0.08\      0.90 ± 0.22      0.41 ± 0.20\     0.32 ± 0.05\      0.13 ± 0.04\      0.26 ± 0.08\      0.36 ± 0.08\      0.34 ± 0.06\
                               *P *=* *0.0033      *P *=* *0.0018    *P *=* *0.0006    *P *=* *0.0077                     *P *=* *0.0056   *P *=* *0.0019    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *=* *0.0006

  fgfr1    0.98 ± 0.01         0.45 ± 0.02\        0.40 ± 0.03\      0.33 ± 0.04\      0.39 ± 0.03\      1.10 ± 0.04      0.95 ± 0.08      0.68 ± 0.05\      0.44 ± 0.02\      0.42 ± 0.03\      0.40 ± 0.03\      0.44 ± 0.05\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *=* *0.0020    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  tgfbr2   0.90 ± 0.05         0.43 ± 0.01\        0.33 ± 0.02\      0.32 ± 0.02\      0.39 ± 0.03\      0.85 ± 0.04      0.87 ± 0.02      0.54 ± 0.02\      0.47 ± 0.02\      0.51 ± 0.03\      0.50 ± 0.02\      0.57 ± 0.07\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *=* *0.0007    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *=* *0.0005

  esr1     0.98 ± 0.03         0.41 ± 0.03\        0.27 ± 0.01\      0.29 ± 0.02\      0.38 ± 0.02\      0.90 ± 0.03      1.04 ± 0.04      0.67 ± 0.02\      0.44 ± 0.02\      0.44 ± 0.02\      0.44 ± 0.02\      0.41 ± 0.02\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *=* *0.0101    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  ptov1    0.56 ± 0.08\        0.40 ± 0.03\        0.20 ± 0.02\      0.21 ± 0.02\      0.29 ± 0.05\      0.65 ± 0.05\     0.56 ± 0.03\     0.25 ± 0.03\      0.14 ± 0.02\      0.24 ± 0.02\      0.27 ± 0.03\      0.28 ± 0.03\
           *P *=* *0.0028      *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *=* *0.0110   *P *=* *0.0019   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  sox17    1.01 ± 0.05         0.40 ± 0.06\        0.43 ± 0.02\      0.35 ± 0.04\      0.40 ± 0.02\      0.90 ± 0.08      1.02 ± 0.04      0.56 ± 0.04\      0.34 ± 0.01\      0.37 ± 0.01\      0.27 ± 0.02\      0.28 ± 0.03\
                               *P *\<* *0.0001     *P *=* *0.0006    *P *\<* *0.0001   *P *\<* *0.0001                                     *P *=* *0.0044    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  egfr     1.19 ± 0.04         0.38 ± 0.02\        0.53 ± 0.02\      0.52 ± 0.06\      0.63 ± 0.05\      1.53 ± 0.08\     0.77 ± 0.02      0.41 ± 0.03\      0.29 ± 0.02\      0.29 ± 0.03\      0.30 ± 0.03\      0.43 ± 0.04\
                               *P *\<* *0.0001     *P *=* *0.0062    *P *=* *0.0022    *P *=* *0.0064    *P *=* *0.0011                    *P *=* *0.0013    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *=* *0.0004

  ptrf     0.90 ± 0.03         0.34 ± 0.02\        0.31 ± 0.02\      0.29 ± 0.02\      0.35 ± 0.02\      1.13 ± 0.04      0.79 ± 0.01\     0.39 ± 0.03\      0.25 ± 0.01\      0.25 ± 0.01\      0.28 ± 0.02\      0.29 ± 0.03\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0258   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  igfbp2   1.07 ± 0.16         0.34 ± 0.06\        0.64 ± 0.13\      0.63 ± 0.11\      0.58 ± 0.06\      2.15 ± 0.42\     2.70 ± 1.84      1.15 ± 0.62       0.38 ± 0.03\      0.43 ± 0.11\      0.32 ± 0.04\      0.36 ± 0.10\
                               *P *\<* *0.0001     *P *=* *0.0122    *P *=* *0.0056    *P *=* *0.0005    *P *=* *0.0002                                      *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  tgfb3    1.14 ± 0.07         0.30 ± 0.02\        0.47 ± 0.03\      0.41 ± 0.03\      0.41 ± 0.04\      1.06 ± 0.05      0.86 ± 0.06      0.31 ± 0.01\      0.26 ± 0.01\      0.25 ± 0.01\      0.37 ± 0.03\      0.53 ± 0.04\
                               *P *\<* *0.0001     *P *=* *0.0002    *P *\<* *0.0001   *P *\<* *0.0001                                     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *=* *0.0002

  vegfb    0.93 ± 0.02         0.28 ± 0.02\        0.22 ± 0.03\      0.20 ± 0.03\      0.27 ± 0.01\      1.06 ± 0.06      0.81 ± 0.03      0.40 ± 0.04\      0.23 ± 0.01\      0.26 ± 0.01\      0.28 ± 0.02\      0.32 ± 0.02\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *=* *0.0003    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  ar       1.07 ± 0.04         0.28 ± 0.01\        0.26 ± 0.01\      0.31 ± 0.02\      0.37 ± 0.02\      0.99 ± 0.03      1.01 ± 0.04      0.51 ± 0.02\      0.41 ± 0.01\      0.45 ± 0.01\      0.48 ± 0.01\      0.51 ± 0.02\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *=* *0.0003    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  igfbp6   0.80 ± 0.03         0.26 ± 0.02\        0.19 ± 0.01\      0.19 ± 0.02\      0.19 ± 0.01\      0.81 ± 0.03      0.75 ± 0.04      0.34 ± 0.01\      0.21 ± 0.01\      0.21 ± 0.01\      0.18 ± 0.01\      0.19 ± 0.02\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *=* *0.0003    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  egf      0.93 ± 0.06         0.26 ± 0.05\        0.38 ± 0.02\      0.34 ± 0.02\      0.40 ± 0.06\      1.20 ± 0.10      0.61 ± 0.04\     0.29 ± 0.02\      0.22 ± 0.02\      0.33 ± 0.01\      0.32 ± 0.03\      0.35 ± 0.02\
                               *P *\<* *0.0001     *P *=* *0.0003    *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0036   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  mapk3    1.11 ± 0.03         0.24 ± 0.01\        0.21 ± 0.02\      0.21 ± 0.01\      0.22 ± 0.01\      1.13 ± 0.04      0.78 ± 0.02\     0.34 ± 0.02\      0.19 ± 0.01\      0.19 ± 0.01\      0.19 ± 0.01\      0.19 ± 0.01\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0497   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  tnxb     0.98 ± 0.02         0.21 ± 0.02\        0.30 ± 0.01\      0.27 ± 0.03\      0.30 ± 0.02\      1.04 ± 0.02      0.89 ± 0.03      0.31 ± 0.01\      0.17 ± 0.01\      0.19 ± 0.01\      0.23 ± 0.01\      0.24 ± 0.03\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  bcl2     1.10 ± 0.01         0.21 ± 0.02\        0.24 ± 0.02\      0.23 ± 0.01\      0.23 ± 0.01\      1.12 ± 0.08      0.59 ± 0.03\     0.17 ± 0.02\      0.10 ± 0.01\      0.12 ± 0.01\      0.16 ± 0.01\      0.18 ± 0.01\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0002   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  igf1r    1.00 ± 0.04         0.20 ± 0.01\        0.15 ± 0.01\      0.11 ± 0.01\      0.12 ± 0.01\      1.04 ± 0.02      0.59 ± 0.01\     0.21 ± 0.02\      0.09 ± 0.01\      0.08 ± 0.01\      0.09 ± 0.01\      0.09 ± 0.01\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0005   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  pik3r2   0.83 ± 0.02         0.18 ± 0.01\        0.14 ± 0.01\      0.15 ± 0.02\      0.20 ± 0.02\      0.84 ± 0.05      0.82 ± 0.03      0.31 ± 0.02\      0.16 ± 0.01\      0.20 ± 0.02\      0.21 ± 0.01\      0.18 ± 0.02\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  sox4     0.83 ± 0.03         0.17 ± 0.01\        0.16 ± 0.01\      0.16 ± 0.02\      0.20 ± 0.01\      0.73 ± 0.04      0.61 ± 0.11\     0.19 ± 0.02\      0.13 ± 0.01\      0.18 ± 0.01\      0.23 ± 0.01\      0.22 ± 0.02\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0139   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  lepr     1.13 ± 0.03         0.16 ± 0.01\        0.17 ± 0.01\      0.12 ± 0.02\      0.13 ± 0.01\      1.26 ± 0.04\     0.79 ± 0.06      0.28 ± 0.03\      0.12 ± 0.01\      0.10 ± 0.01\      0.07 ± 0.01\      0.07 ± 0.01\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *=* *0.462                     *P *=* *0.0001    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  gpr30    1.04 ± 0.04         0.16 ± 0.01\        0.20 ± 0.04\      0.16 ± 0.01\      0.17 ± 0.01\      1.10 ± 0.05      0.74 ± 0.08      0.23 ± 0.03\      0.11 ± 0.01\      0.11 ± 0.01\      0.11 ± 0.01\      0.12 ± 0.02\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  fgfr2    1.25 ± 0.07         0.15 ± 0.02\        0.17 ± 0.01\      0.17 ± 0.04\      0.13 ± 0.01\      1.03 ± 0.05      0.95 ± 0.02      0.25 ± 0.03\      0.13 ± 0.01\      0.12 ± 0.01\      0.10 ± 0.01\      0.12 ± 0.02\
                               *P *\<* *0.0001     *P *=* *0.0001    *P *\<* *0.0001   *P *\<* *0.0001                                     *P *=* *0.0003    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  ctsf     1.02 ± 0.02         0.14 ± 0.02\        0.11 ± 0.01\      0.08 ± 0.01\      0.10 ± 0.01\      1.03 ± 0.04      0.71 ± 0.04\     0.19 ± 0.02\      0.07 ± 0.01\      0.07 ± 0.01\      0.06 ± 0.01\      0.06 ± 0.01\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0068   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  kgf      1.28 ± 0.15         0.14 ± 0.01\        0.16 ± 0.01\      0.18 ± 0.02\      0.24 ± 0.02\      1.12 ± 0.07      1.02 ± 0.04      0.41 ± 0.02\      0.31 ± 0.01\      0.36 ± 0.03\      0.29 ± 0.01\      0.28 ± 0.020\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *=* *0.0007    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  igfbp3   1.10 ± 0.06         0.14 ± 0.01\        0.15 ± 0.01\      0.13 ± 0.02\      0.13 ± 0.02\      1.18 ± 0.11      0.65 ± 0.05\     0.21 ± 0.01\      0.12 ± 0.01\      0.10 ± 0.01\      0.09 ± 0.01\      0.11 ± 0.01\
                               *P *\<* *0.0001     *P *=* *0.0003    *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0379   *P *=* *0.0005    *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  hdac5    0.74 ± 0.06\        0.13 ± 0.02\        0.09 ± 0.01\      0.08 ± 0.01\      0.09 ± 0.01\      0.88 ± 0.07      0.58 ± 0.05\     0.19 ± 0.03\      0.06 ± 0.01\      0.07 ± 0.01\      0.08 ± 0.01\      0.06 ± 0.01\
           *P *=* *0.0438      *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0023   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  vegfc    1.06 ± 0.08         0.11 ± 0.01\        0.11 ± 0.01\      0.11 ± 0.01\      0.13 ± 0.01\      1.02 ± 0.05      0.78 ± 0.06      0.30 ± 0.01\      0.18 ± 0.01\      0.15 ± 0.01\      0.16 ± 0.01\      0.16 ± 0.01\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                                     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  txnip    1.29 ± 0.05\        0.08 ± 0.01\        0.09 ± 0.01\      0.08 ± 0.01\      0.10 ± 0.01\      1.32 ± 0.06\     0.68 ± 0.03\     0.15 ± 0.01\      0.09 ± 0.01\      0.09 ± 0.01\      0.07 ± 0.01\      0.07 ± 0.01\
           *P *=* *0.0246      *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *=* *0.0160   *P *=* *0.0144   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001

  ccng2    0.99 ± 0.03         0.08 ± 0.01\        0.08 ± 0.01\      0.06 ± 0.01\      0.06 ± 0.01\      1.11 ± 0.02      0.58 ± 0.03\     0.10 ± 0.02\      0.04 ± 0.01\      0.04 ± 0.01\      0.05 ± 0.01\      0.06 ± 0.01\
                               *P *\<* *0.0001     *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001                    *P *=* *0.0003   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001   *P *\<* *0.0001
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results were expressed as mean ± SEM (*n* = 4--8 mice/group). Significance of the observed effects was evaluated using Student\'s *t*-test. Gray highlight represents the maximum of regulation

![Comparison of E~2~ and E~4~ on uterine gene regulation in ovariectomized mice\
Seven-week-old ovariectomized C57Bl/6J mice were subcutaneously injected with vehicle (Ctrl, castor oil), E~2~ (8 μg/kg), or E~4~ (1 mg/kg) and were euthanized 6 h after treatment. Data obtained from 96.96 Dynamic Arrays were used to generate a cluster diagram of the significant gene expression changes. Each vertical line represents a single gene. Each horizontal line represents an individual sample. Genes that were up-regulated at least twofold following E~2~ administration relative to placebo are in red, whereas down-regulated genes are in green. The color intensity indicates the degree of variation in expression.Clustering pattern of the gene whose expression is affected by E~2~ and/or E~4~.](emmm0006-1328-f3){#fig03}

We next examined the relationship between gene regulation patterns and uterotrophic effects of E~2~ versus E~4~, noting histological changes and uterine epithelial cell proliferation. Luminal epithelial height (LEH) and stromal height (SH) were significantly and similarly increased with E~2~ (8 μg/kg) and E~4~ (1 mg/kg) 24 h after subcutaneous administration (Fig [4](#fig04){ref-type="fig"}), without significant effects for doses of E~4~ \< 1 mg/kg (Fig [4](#fig04){ref-type="fig"}A and B, and Supplementary Fig S3A and B). Accordingly, a maximal induction of epithelial proliferation, detected by Ki-67 nuclear staining (Fig [4](#fig04){ref-type="fig"}C and D), was observed in mice treated with either E~2~ 8 μg/kg or E~4~ 1 mg/kg alone. Lower doses of E~4~ elicited moderate to minor epithelial proliferation (Supplementary Fig S3C and D). To further analyze the interactions between E~4~ and E~2~ on ERα transcriptional activity, we then studied the effect of their combined impact on uterus. E~2~ (8 μg/kg) and E~4~ (given at either 200 μg/kg or 1 mg/kg) were co-administrated, and gene expression in the uterus was analyzed 6 h later. As shown in the Supplementary Fig S4, the gene expression profile of the E~2~--E~4~ combination was similar to that elicited by E~2~ alone for most of the genes (cluster 1). In some cases an intermediate response was observed using co-administration of E~2~--E~4~ compared to E~2~ alone (cluster 2), probably due to the lower potency of E~4~ (1 mg/kg) than those of E~2~ to induce maximal gene regulation for these genes (Fig [3](#fig03){ref-type="fig"}, middle panel). Importantly, the histological changes and uterine epithelial cell proliferation induced by E~2~ (8 μg/kg) and E~4~ (200 μg/kg or 1 mg/kg) co-treatment did not differ from those elicited by E~2~ (8 μg/kg) alone (Fig [4](#fig04){ref-type="fig"}). Taken together, these results demonstrate that E~4~ acts as a less potent estrogen on both gene expression and epithelial proliferation in the uterus, close to results obtained previously in rat uterus (Holinka & Gurpide, [@b22]).

![Comparison of E~2~ and E~4~ on uterine histological parameters and epithelial proliferation\
Seven-week-old ovariectomized C57Bl/6J mice were injected subcutaneously with vehicle (Ctrl, castor oil), E~2~ (8 μg/kg), and/or E~4~ (200 μg/kg or 1 mg/kg) and were euthanized 24 h after treatment.\
A, B Luminal epithelial height (LEH) (A) and stromal height (SH) (B) were measured.\
C, D Representative (C) and quantification (D) of Ki-67 detection in transverse uterus sections (scale bar = 50 μm).\
Data information: Results are expressed as mean ± SEM. To test the respective roles of each treatment, a one-way ANOVA was performed and a Bonferroni\'s multiple comparison test (*n* = 4--6 mice/group).](emmm0006-1328-f4){#fig04}

E~4~ induces an atheroprotective effect in an ERα-dependent manner
------------------------------------------------------------------

Since estrogens exert many beneficial effects on the arteries (Arnal *et al*, [@b5]), we assessed the impact of E~4~ on the prevention of atheroma. For this aim, we examined lipid deposition at the aortic sinus from ERα^+/+^LDLr^−/−^ or ERα^−/−^LDLr^−/−^ (Low Density Lipoprotein receptor) mice fed a high-cholesterol diet supplemented or not with E~4~ (0.6 and 6 mg/kg/day), a well-recognized model to study atheroprotective effects of estrogens (Mallat & Tedgui, [@b32]; Weber *et al*, [@b51]). E~4~ dose-dependently prevented lipid deposition in ovariectomized ERα^+/+^LDLr^−/−^ mice (Fig [5](#fig05){ref-type="fig"}A and B), decreasing the atheroma deposit by up to 80%, a level of protection similar to that obtained using a high dose of E~2~ (80 μg/kg/jour) (Billon-Gales *et al*, [@b7]). As previously observed with E~2~, this effect was completely abolished in ERα^−/−^LDLr^−/−^ mice, indicating that ERα is necessary to mediate the atheroprotective effect of E~4~ (Fig [5](#fig05){ref-type="fig"}A and B). Interestingly, expression of the most strongly induced gene by E~2~ in the aorta, Gremlin 2 (Grem2) (Schnoes *et al*, [@b40]) was found to be regulated by the highest dose of E~4~ in ERα^+/+^LDLr^−/−^, but not in ERα^−/−^LDLr^−/−^ mice (Fig [5](#fig05){ref-type="fig"}C), emphasizing another aspect of the ERα-dependent nuclear regulation by E~4~.

![E~4~ prevents aortic sinus lipid deposition in hypercholesterolemic mice\
Four-week-old ovariectomized ERα^+/+^LDL-r^−/−^ or ERα^−/−^LDL-r^−/−^ mice were switched to atherogenic diet from the age of 6--18 weeks added with placebo (Ctrl) or E~4~ (0.6 or 6 mg/kg/day).\
A, B Representative micrographs of Oil red-O (ORO) lipid-stained cryosections of the aortic sinus (A) and quantification of lipid deposition (B) are represented.\
C Gremlin 2 (*Grem2*) mRNA level from aorta of these mice was quantified by qPCR and normalized to *Tpt1* mRNA levels. Result was expressed according to the level in aorta from placebo set as 1.\
Data information: Results are expressed as mean ± SEM. Significance of the observed effects was evaluated using one-way or two-way ANOVA followed by Bonferroni\'s *post hoc* test (*n* = 4--8 mice/group).](emmm0006-1328-f5){#fig05}

As previously observed with E~2~ (Billon-Gales *et al*, [@b7]), E~4~ (6 mg/kg/day) decreased total plasma cholesterol in ERα^+/+^LDLr^−/−^ but not in ERα^−/−^LDLr^−/−^ mice. However, in contrast to the action of E~2~, no change of HDL cholesterol level was observed in E~4~ treated mice (Table [3](#tbl3){ref-type="table"}). As expected from the acute dose experiments, a dose-dependent uterine hypertrophy was observed in mice receiving E~4~ chronically, and this effect was totally abolished in ERα^−/−^LDLr^−/−^ mice, further demonstrating the crucial role of ERα in E~4~ uterotrophic activity (Table [3](#tbl3){ref-type="table"}).

###### 

Effect of E~4~ (0.6 or 6 mg/kg/day) treatment on body weight, uterine weight, plasma lipid concentrations, and Oil-red O (ORO) positive area at the aortic sinus in 18-week-old ERα^+/+^LDLr^−/−^ or ERα^−/−^LDLr^−/−^ mice

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                            ERα^+/+^LDLr^−/−^   ERα^−/−^ LDLr^−/−^   *P*, two-factor ANOVA                                                                 
  ------------------------- ------------------- -------------------- ----------------------- ---------------- ---------------- ---------------- ---- ----- ----------------
  Body weight (g)           21.5 ± 0.9          18.7 ± 0.6\          16.2 ± 0.3\             20.9 ± 0.8       23.2 ± 0.5       22.0 ± 1.1       --   --    *P *=* *0.0004
                                                *P *=* *0.0187       *P *\<* *0.0001                                                                       

  Uterine weight (mg)       6 ± 1               31 ± 3\              71 ± 7\                 3 ± 1            4 ± 1            6 ± 1            --   --    *P *=* *0.0001
                                                *P *\<* *0.0001      *P *\<* *0.0001                                                                       

  Total Chol. (mg/dl)       1152.8 ± 142.2      868.4 ± 154.6        552.6 ± 44.0\           1102.2 ± 205.3   1356.5 ± 124.5   1633.3 ± 276.3   --   --    *P *=* *0.0052
                                                                     *P *=* *0.0065                                                                        

  HDL Chol. (mg/dl)         62.3 ± 9.8          77.2 ± 15.1          63.7 ± 4.9              56.9 ± 14.9      61.9 ± 6.2       82.6 ± 24.1      NS   NS    NS

  ORO area (×10^3^ µm^2^)   141 ± 11            91 ± 13\             37 ± 5\                 133 ± 23         140 ± 14         151 ± 28         --   ^-^   *P *=* *0.0028
                                                *P *=* *0.0369       *P *\<* *0.0001                                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results were expressed as mean ± SEM. Significance of the observed effects was evaluated using two-way ANOVA. When an interaction was observed between the 2 factors, effect of E~4~ treatment was studied in each genotype using a Bonferroni\'s *post hoc* test (*n* = 4--8 mice/group)

E~4~ fails to increase endothelial NO production and to accelerate endothelial healing
--------------------------------------------------------------------------------------

We then tested the effect of E~4~ on two other important vasculoprotective actions of estrogens, namely the acceleration of reendothelialization (Brouchet *et al*, [@b11]; Chambliss *et al*, [@b12]) and activation of eNOS (Wu *et al*, [@b52]), both of which are known to involve ERα MISS in the endothelium (Adlanmerini *et al*, [@b4]). First, although E~2~ promoted endothelial healing in the model of carotid artery electric injury, no effect was observed with E~4~, regardless of the dose employed (0.3, 1 or 6 mg/kg/day) (Fig [6](#fig06){ref-type="fig"}A). Second, we tested the effect of E~4~ on eNOS activation in aortae by measuring eNOS phosphorylation (Fig [6](#fig06){ref-type="fig"}B) and NO production using a NO-specific amperometric probe. Whereas E~2~ (10^−8^ M) rapidly and nicely induced eNOS phosphorylation (Fig [6](#fig06){ref-type="fig"}B) and NO production (Fig [6](#fig06){ref-type="fig"}C) in aortae, E~4~ (10^−6^ M) failed to produce these effects (Fig [6](#fig06){ref-type="fig"}B and C). Together, these results suggest that E~4~ is not able to elicit two major endothelial actions known to be MISS ERα dependent, namely acceleration of reendothelialization and activation of eNOS.

![E~4~ fails to accelerate reendothelialization and to increase NO production\
Seven-week-old ovariectomized C57Bl/6J mice were given placebo (Ctrl), E~2~ (80 μg/kg/day) or E~4~ (0.3--6 mg/kg/day), or E~2~ (80 μg/kg/day) + E~4~ (6 mg/kg/day) for 2 weeks. Electric injury was applied to the distal part (3 mm precisely) of the common carotid artery, and the endothelial regeneration process was evaluated 3 days postinjury. Quantification of the reendothelialized area evaluated by Evans blue staining, and results were expressed as mean ± SEM (*n* = 7--23 mice per group). Significance of the observed effects was evaluated using one-way ANOVA followed by Bonferroni\'s *post hoc* test.Quantification expressed as mean ± SEM (*n* = 7 mice per group, upper panel) and representative Western blot (lower panel) of phospho-eNOS/eNOS abundance in isolated aortae treated by E~2~ (10^−8^ M), E~4~ (10^−6^ M), combination of both E~2~ and E~4~ or acetylcholine (Ach) used as a positive control during 30 min. Significance of the observed effects was evaluated using one-way ANOVA followed by Bonferroni\'s *post hoc* test (*n* = 8 mice/group).Representative trace of *ex vivo* amperometric measurements of NO release of aortae from 10- to 12-week-old C57Bl/6J mice exposed to E~2~ (10^−8^ M) or E~4~ (10^−6^ M) during 5 min.For cotreatment experiment, E~4~ (10^−6^ M) or vehicle (DMSO) was pre-incubated during 10 min prior to E~2~ (10^−8^ M) treatment. To test the respective roles of each treatment, a one-way ANOVA was performed followed by a Bonferroni\'s *post hoc* test.\
Source data are available online for this figure.](emmm0006-1328-f6){#fig06}

The fact that E~4~ failed to elicit responses that are mediated via membrane ERα raises the question of whether this is due to the failure of E~4~ to bind to membrane ERα or the failure of membrane ERα to become activated by E~4~ binding, in which case E~4~ would be expected to have antagonist activity on this signaling pathway. To address this question, we first co-administrated E~4~ (6 mg/kg/day) and E~2~ (80 μg/kg/day), and found that this combination failed to accelerate endothelial healing (Fig [6](#fig06){ref-type="fig"}A). Then, we tested the effect of E~2~ (10^−8 ^M) on NO production by aortae *ex vivo* exposed to E~4~ (10^−6 ^M) 10 min before, and we found that E~4~ inhibited the stimulatory action of E~2~ (Fig [6](#fig06){ref-type="fig"}D). Accordingly, the combination of E~2~ (10^−8 ^M) and E~4~ (10^−6 ^M) did not stimulate eNOS phosphorylation in aortae (Fig [6](#fig06){ref-type="fig"}B). Altogether, E~4~ is not only devoid of ERα MISS in the endothelium, but E~4~ is also able to partially antagonize these E~2~ MISS effects.

E~4~ promotes ERα-*src* interaction less efficiently than does E~2~ but induces similar ERE-dependent transcriptional activity in MCF-7
---------------------------------------------------------------------------------------------------------------------------------------

Finally, we approached the impact of E~4~ on ERα MISS in the breast cancer cell line, MCF-7. We failed to detect reliably the activation of MAPK by E~2~, in agreement with some authors (Gaben *et al*, [@b17]). We studied another well-accepted aspect of ERα MISS, that is, ERα interaction with the tyrosine kinase src using the Duolink technique (Soderberg *et al*, [@b42]). We found that E~2~ (10^−8^ M) favored this interaction, whereas a 100-fold higher dose (E~4~ 10^−6^ M) was less efficient in inducing this aspect of MISS (Fig [7](#fig07){ref-type="fig"}A). Importantly, when administrated together, the combination totally abrogated the ERα-src interaction, suggesting that, as shown above in endothelial cells, E~4~ was able to antagonize the action of E~2~ on ERα MISS. We also explored the impact of E~2~ 10^−8^ M, E~4~ 10^−6^ M, and their combination on the gene expression of MCF-7. As shown in Fig [7](#fig07){ref-type="fig"}B, E~2~ 10^−8^ M and E~4~ 10^−6^ M similarly up-regulated the expression of genes containing ERE in their regulatory sequences, such as the gene regulated by estrogen in breast cancer 1 (GREB1) (Sun *et al*, [@b43]), the progesterone receptor (PR) (Kraus *et al*, [@b28]), and the chemokine (C-X-C motif) ligand 12 (CXCL12) (Boudot *et al*, [@b10]). Interestingly, and in striking contrast with the MISS effect, E~2~--E~4~ combination elicited the same induction than each isolated compound, showing no detectable interaction in these ERα nuclear actions.

![E~4~ promotes ERα-*src* interaction less efficiently than does E~2~ but induces similar ERE-dependent transcriptional activity in MCF-7\
MCF-7 cells were grown in medium containing 2.5% charcoal-stripped serum with vehicle or with E~2~ (10^−8^ M), E~4~ (10^−6^ M) or in combination for 5 min. After fixation, *in situ* PLA for ERα-Src dimers was performed with ERα- and Src-specific antibodies. The detected dimers are represented by red dots, and the nuclei were counterstained with DAPI (blue). Quantification of the number of signals per cell was performed by computer-assisted analysis as reported in the Materials and Methods section. Values correspond to the mean ± SEM of at least three separate experiments, and columns with different superscripts differ significantly using Student\'s *t*-test.mRNA level of the indicated gene from MCF-7 cells treated with vehicle, E~2~ (10^−8^ M), E~4~ (10^−6^ M) or combined treatment and analyzed after 24 h by qPCR. Values correspond to the mean ± SD of at least three separate experiments. To test the respective roles of each treatment, a one-way ANOVA was performed and a Bonferroni\'s multiple comparison test.](emmm0006-1328-f7){#fig07}

Discussion
==========

Estetrol (E~4~), a physiological estrogen with four hydroxyl groups produced only by the fetal liver, appears to be human specific, but its physiological role is unknown. Furthermore, very few data are available concerning its molecular mechanisms of action. In this study, we demonstrate through *in vitro* and *in vivo* experiments that E~4~ is able to induce ERα transcriptional activity (about 100-fold above the doses of E~2~ required for the responses considered). Accordingly, the positioning of E~4~ in the ligand-binding pocket is very similar to that of E~2~, leading to a positioning of helix 12 and AF-2 availability that are nearly identical to that elicited by E~2~. Notably, although the affinity of E~4~ for ERα is 100-fold less than E~2~, the ERα complex with E~4~ is able to bind the important coactivator SRC3 as the complex with E~2~. We and others previously demonstrated that endometrial proliferation is highly dependent on the ERα nuclear actions, since this effect is abrogated in ERαAF-2^0^ and ERαAF-1^0^ mice (Abot *et al*, [@b1]), whereas it is fully preserved using a mouse with a point mutation of the palmitoylation site of ERα (C451A-ERα) that leads to membrane-specific loss of function of ERα (Adlanmerini *et al*, [@b4]). The potent atheroprotective effect observed in response to E~4~ also fits nicely not only with an ERα-dependent effect, as demonstrated by its abrogation in ERα^−/−^ mice, but also with the nuclear action of ERα. Indeed, we previously demonstrated that E~2~ failed to induce its atheroprotective action using AF-2^0^LDLR^−/−^ mice, highlighting the importance of nuclear/transcriptional actions of ERα for atheroprotection (Billon-Gales *et al*, [@b8]).

In contrast, E~4,~ even at high doses, is not able to elicit major endothelial actions known to be membrane ERα dependent, namely an increase in eNOS phosphorylation, in NO production, or an acceleration of reendothelialization (Chambliss *et al*, [@b12]; Adlanmerini *et al*, [@b4]). Furthermore, it antagonizes partially these MISS effects of ERα in response to E~2~. We also found that although E~4~ promotes some level of ERα-src interaction, E~2~/E~4~ combination does not promote any interaction. Already, H. Coelingh Bennink *et al* reported in the cancer-induced rat model that mammary tumor formation induced by DMBA treatment was stimulated by E~2~ and EE, but prevented by E~4~ (Coelingh Bennink *et al*, [@b13]). Very recently, it has been demonstrated that E~2~ through a MISS effect enhanced the migration and invasiveness of human T47D breast carcinoma cells (Giretti *et al*, [@b18]). In contrast, E~4~ failed to stimulate and even antagonized the stimulation of T47D cells migration and invasion through matrigel by E~2~. According to our current understanding of MISS effects in breast cancer (Acconcia & Marino, [@b3]; Le Romancer *et al*, [@b31]), these data suggest that in this context E~4~ could have a safer profile than classic estrogens. Altogether, E~4~ appears to behave as a full or partial membrane ERα antagonist.

The structure as well as the conformation of ERα at the plasma membrane remains unclear, although palmitoylation appears to play an important role in its membrane localization and extranuclear-initiated actions (Acconcia *et al*, [@b2]; Adlanmerini *et al*, [@b4]). It thus appeared to us that comparing the physical interaction characteristics of these two estrogens, E~2~ and E~4~, in artificial membranes could shed some light to the lack of MISS action of E~4~. E~4~ was found to be almost as soluble as E~2~ in artificial membranes, ruling out the possibility that the lack of membrane signaling by E~4~ could be the result of its lack of availability in this cell compartment. In addition, whereas E~2~ was found to be in equilibrium between two orientations in the bilayer, E~4~ had a preferential orientation with its phenol group oriented toward interface and the three hydroxyl groups thus being at the hydrophobic core of the membrane. This orientation is rather counterintuitive, although an efficient intramolecular network of hydrogen bonds among the three D-ring OH groups might be masking their polarity more effectively than the lone 17β-OH in E~2~. The relationship between membrane orientation of an estrogen and its access to the ligand-binding site in membrane ERα, however, is at this point a matter of speculation, but it is clear that both E~2~ and E~4~ bind to ERα regardless of whether it is localized in the nucleus or the plasma membrane.

It is important to underline that the molecular mechanisms that mediate MISS effects of estrogen are far to be fully understood. The downstream target regulated by the ERα MISS involved various post-transcriptional modifications which probably highly differ between cell types. In endothelial cells, PI3K, Akt kinase, ERK1/2, striatin, and phosphorylation of eNOS have been described to be required for ERα MISS, whereas in vascular smooth muscle cells, expression and activity of several phosphatases such as MKP-1, SHP-1, PTEN, and PP2A mediate this pathway (Ueda & Karas, [@b45]). Since E~4~ is specific for humans and is produced only by the fetal liver, it is tempting to speculate that E~4~ might be conferring a very specific but important modulating effect of E~2~ action on fetal development, especially on brain development, as the nervous system appears to be largely influenced by MISS actions (Vasudevan & Pfaff, [@b47]).

Defect of E~4~ action via the membrane ERα pathway could also play a role on gene expression profiles and phenotypic effects of ERα action in organs that are dependent on both nuclear and membrane effects. Several authors proposed that nuclear action of ERα and of other transcription factors are regulated by MISS actions of estrogens (O\'Malley & McGuire, [@b37]; Bjornstrom & Sjoberg, [@b9]; Lannigan, [@b30]; La Rosa *et al*, [@b29]), and the respective level of dependency of tissues on both nuclear and membrane effects could also be determined thanks to C451A-ERα and ERαAF-2^0^ mice. Although this cross talk was not observed for cell proliferation in uterus (Adlanmerini *et al*, [@b4]), it could be important in other tissues.

This original profile of ERα activation, uncoupling nuclear and membrane activation is, to the best of our knowledge, unique and characterizes E~4~ as a natural endogenous selective ER modulator (Table [4](#tbl4){ref-type="table"}), reinforcing the idea that medical applications should be pursued further. Indeed, E~4~, in combination with a progestin, inhibits ovulation during the reproductive life (Coelingh Bennink *et al*, [@b15]), or alleviates the climacteric symptoms after menopause (Holinka *et al*, [@b23]). As mentioned in the introduction, two recent phase 2 clinical trials evaluated the contraceptive efficacy of 5--20 mg E~4~ and levonorgestrel or drospirenone as a progestin. The first study evaluated ovulation inhibition in 91 women (18--35 year old) by measuring follicular size and endometrial thickness by ultrasound and evaluating the plasma levels of FSH, LH, E~2~, and progesterone. No ovulation was observed during the three cycles of treatment. The second study evaluated the bleeding profile in 330 young women over six cycles. An excellent bleeding and spotting profile clearly demonstrated the capacity of E~4~ to maintain a stable endometrium that was superior to the control group treated with E~2~ and dienogest. Lack of ovulation in all women was also verified by measuring the urinary excretion of pregnanediol, a progesterone metabolite. Remarkably, changes in SHBG, corticosteroid binding globulin (CBG), angiotensinogen, triglycerides, or coagulation proteins were minimal and considerably lower than in the comparator group receiving a combination of EE and drospirenone. Altogether, these experimental and clinical studies indicate that E~4~ should now be considered as a natural SERM. It is able to stimulate the endometrium, but it has no or only a minimal impact on the liver function. Dedicated experimental studies and randomized clinical trials of E~4~ are now needed, as better therapeutic alternatives are greatly needed by physicians and patients both in the field of oral contraception and as agents to replace the loss of beneficial estrogen effects resulting from the menopause.

###### 

Current understanding of the impact of E~2~ and E~4~ on nuclear versus membrane initiated steroid signaling (MISS) ERα-mediated effects

  Estrogens                       Cell or tissue effects                
  ------------------------------- ------------------------ ----- ------ -----
  E~2~                            +++                      +++   +++    +++
  E~4~                            +++                      +++   \+     0
  E~2~ + E~4~                     +++                      +++   0      0/+
  Prominent mechanism of action   Nuclear                        Miss   

Materials and Methods
=====================

Expression purification and crystallization of ERα ligand-binding domain
------------------------------------------------------------------------

ERα-LDB was expressed with a N-terminal Histidine tag in *E. coli* (BL21 DE3) and induced with isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside (IPTG) for 16 h at 18°C. Cell pellets were lysed in 5 pellet volumes of lysis buffer \[50 mM Tris pH7.6, 500 mM NaCl, 10% glycerol, 0.05% β-octyl glucoside, 10 mM imidazole, 5 mM β-mercaptoethanol, protease inhibitor (Roche) and 0.1 mg/ml lysozyme\]. The lysates were centrifuged at 30,000 *g* for 30 min, and the supernatant was collected and loaded on a Ni-affinity resin. ERα-LDB protein was eluted with lysate buffer containing 500 mM imidazole. ERα-LDB was further purified on a size exclusion column. ERα was crystallized in complex with E~2~, E~3~ or E~4~, and GRIP peptide using a commercial screen formulation Index (Hampton Research) (Hsieh *et al*, [@b24]) Data collection was performed on single crystals at sector 19 (Structural Biology Center Collaborative Access Team at Agronome National Laboratory).

Cell culture and transfection assays
------------------------------------

MCF-7 cells were maintained in DMEM (Sigma-Aldrich) supplemented with 10% fetal calf serum (FCS) (Biowest) and antibiotics (Sigma-Aldrich) at 37°C in 5% CO~2~. One day before treatment, cells growing in 10 cm diameter dishes were placed in phenol red-free DMEM (Sigma-Aldrich) containing 2.5% charcoal-stripped FCS (Biowest). Cells were then treated for 24 h with E~2~ (10^−8^ M), E~4~ (10^−6^ M), combined treatment or ethanol.

HepG2 and HeLa cells were maintained in DMEM (Sigma-Aldrich) supplemented with 10% fetal calf serum (FCS) (Biowest) and antibiotics (Sigma-Aldrich) at 37°C in 5% CO~2~. Transfections were carried out using jetPEI reagent according to manufacturer\'s instructions (Polyplus). One day before transfection, cells were plated in 24-well plates at 50% confluence. One hour prior to transfection, the medium was replaced with phenol red-free DMEM (Sigma-Aldrich) containing 2.5% charcoal-stripped FCS (Biowest). Transfection was carried out with 100 ng of ERE-TK promoter driven renilla luciferase (luc) reporter, 100 ng of CMV-β galactosidase (Gal) internal control, and 50 ng of pCR3.1, pCR-ERα, pCR-ERα Δ79, or pCR-ERαAF-1^0^ expression vectors. Following an overnight incubation, cells were treated for 24 h with E~2~, E~4~, or ethanol (vehicle control). Cells were then harvested, and luciferase and β-galactosidase assays were performed as previously described (Penot *et al*, [@b38]).

Mice
----

All procedures involving experimental animals were performed in accordance with the principles and guidelines established by the National Institute of Medical Research (INSERM) and were approved by the local Animal Care and Use Committee. ERα-null mice (ERα^−/−^) were generated as previously described (Billon-Gales *et al*, [@b7]) and were kindly provided by Pr P. Chambon (Strasbourg, France). To generate the double-deficient mice, LDLr^−/−^ female mice, purchased from Charles River (L\'Arbresle, France), were crossed with ERα^+/−^ mice. The mice were anesthetized by injection of ketamine (100 mg/kg) and xylazine (10 mg/kg) by intraperitoneal route. To analyze E~4~ uterine action, C57Bl/6J were ovariectomized at 4 weeks of age and were subcutaneously injected with vehicle (castor oil), E~2~, or E~4~ at different doses 3 weeks later. Mice were sacrificed 6 or 24 h after a single estrogen injection and uteri were collected.

Analysis of mRNA levels by RT-qPCR
----------------------------------

Tissues were homogenized using a Precellys tissue homogenizer (Bertin Technol., Cedex, France), and total RNA from tissues was prepared using TRIzol (Invitrogen, Carlsbad, CA). One microgram of RNA was reverse transcribed (RT) at 25°C for 10 min and then at 37°C for 2 h in 20 μl final volume using the High Capacity cDNA reverse transcriptase kit (Applied Biosystems). For gene expression in uterus, the 96.96 Dynamic Arrays for the microfluidic BioMark system (Fluidigm Corporation, CA, USA) were used to study by high throughput qPCR the gene expression profile in 6.5 ng cDNA from each sample, as described previously (Abot *et al*, [@b1]). For gene expression in aorta, qPCR was performed using SsoFast EvaGreen Supermix (Bio-Rad) with primers validated by testing the PCR efficiency (Fontaine *et al*, [@b16]). Gene expression was quantified using the comparative C~t~ (threshold cycle) method.

Total RNA from MCF-7 cells was also extracted using TRIzol™ (Invitrogen) according to the manufacturer\'s instructions. cDNAs were generated using MMLV Reverse transcriptase (Invitrogen) and random hexamers (Promega, Madison, WI, USA). Quantitative RT-PCR was performed using the iQ SybrGreen supermix (BioRad, Hercules, CA, USA) on a BioRad MyiQ apparatus. Sequences of the primers used for cDNA amplification in the quantitative RT-PCR experiments are available upon request. Results were normalized to GAPDH expression.

Uterus immunohistochemistry
---------------------------

Four-micrometer paraffin-embedded transverse sections from formalin fixed uterine specimens were dewaxed in toluene and rehydrated through acetone bath to deionized water. Antigen retrieval was performed in 10 mM citrate buffer pH 6.0 for 30 min in a water bath at 95°C. Cooled sections were then incubated in peroxidase blocking solution (Dako) to quench endogenous peroxidase activity. To block non-specific binding, sections were incubated in normal goat serum (Dako) for 20 min at room temperature. Primary antibodies were all rabbit polyclonal antibodies: anti-Ki-67 antigen (Thermo-scientific). Sections were incubated 50 min at room temperature with primary antibodies. The secondary antibody, biotinylated goat anti-rabbit immunoglobulins (Thermo-Scientific), was applied for 25 min at room temperature followed by an HRP-streptavidin solution (Dako) for 25 min. Peroxidase activity was revealed by 3,3′-diaminobenzidine tetrahydrochloride substrate (Dako). Finally, sections were counterstained with Harris hematoxylin, dehydrated and coverslipped. The luminal epithelial height (LEH) and stromal height (SH) were measured from the basal membrane to the apical surface. The values are the mean of ten measurements in each transverse uterus section.

Analyses of atherosclerosis lesions
-----------------------------------

Bilateral ovariectomy was performed at 4 weeks of age. At 6 weeks of age, mice were switched to a hypercholesterolemic atherogenic diet (1.25% cholesterol, 6% fat, no cholate, TD96335, Harlan Teklad, Wisconsin) mixed with E~4~ (calculated to correspond to either 0.6 or 6 mg/kg/day) during 12 weeks. Over-night fasted mice were anesthetized, and blood was collected from the retro-orbital venous plexus. Lipid deposition size was evaluated at the aortic sinus as previously described (Billon-Gales *et al*, [@b7]). Briefly, each heart was frozen on a cryostat mount with OCT compound. One hundred 10-μm thick sections were prepared from the top of the left ventricle, where the aortic valves were first visible, up to a position in the aorta where the valve cusps were just disappearing from the field. After drying for 2 h, the sections were stained with oil red O and counterstained with Mayer\'s hematoxylin. Ten sections out of the 100, each separated by 90 μm, were used for specific morphometric evaluation of intimal lesions using a computerized Biocom morphometry system. The first and most proximal section to the heart was taken 90 μm distal to the point where the aorta first becomes rounded. The mean lesion size (expressed in μm^2^) in these 10 sections was used to evaluate the lesion size of each animal.

Determination of plasma lipids
------------------------------

Total cholesterol was assayed using the CHOD-PAD kit (Horiba ABX, Montpellier, France). The high density lipoprotein (HDL) fraction was isolated from 10 μl of serum and assayed using the 'C-HDL + Third generation' kit (Roche, Lyon, France).

Mouse carotid injury and quantification of reendothelialization
---------------------------------------------------------------

Bilateral ovariectomy was performed at 4 weeks of age, and concomitantly the mice received pellets implanted subcutaneously releasing either placebo, E~2~ (17β-estradiol 0.1 mg, 60 days release, i.e., 80 μg/kg/day, Innovative Research of America, Sarasota, FL) or an osmotic minipump releasing E~4~ (1 or 6 mg/kg/day). After 2 weeks treatment, carotid electric injury was performed as previously described (Brouchet *et al*, [@b11]) and reendothelialization was evaluated after 3 days. Briefly, surgery was carried out with a stereomicroscope (Nikon SMZ800), and the left common carotid artery was exposed via an anterior incision in the neck. The electric injury was applied to the distal part (3 mm precisely) of the common carotid artery with a bipolar microregulator. Three day postinjury, carotid arteries were stained with Evans blue dye and mounted with Kaiser\'s Glycerol gelatin (Merck). Images were acquired using DMR 300 Leica microscope using LAS V3.8 and ImageJ software. Percentage of reendothelialization was calculated relative to the initial deendothelialized area (Brouchet *et al*, [@b11]; Chambliss *et al*, [@b12]).

Western blotting
----------------

Total proteins from aortae were separated on a 10% SDS/PAGE gel and transferred to a nitrocellulose membrane. The primary antibodies used are as follows: pSer1177-eNOS (612392; BD Bioscience), eNOS (610297; BD Bioscience), and β-actin (A2066; Sigma). Revelation was performed using an HRP-conjugated secondary antibody and visualized by ECL detection according to the manufacturer\'s instructions (Amersham Biosciences/GE Healthcare), using ChemiDoc Imaging System (Bio-Rad). Bands were quantified using ImageJ densitometry.

Real-time NO production
-----------------------

Aorta from intact mice (10--12 weeks) was quickly harvested and maintained in 200 μl Krebs--Ringer oxygenated solution containing 2.5 mmol/l glucose at 37°C. A NO-specific amperometric probe \[ISO-NOPF100; World Precision Instruments (WPI), Sarasota, FL\] was implanted directly in the tissue, and NO release was monitored. The aorta was exposed to E~2~ (10^−8^ M) or E~4~ (10^−6 ^M) during 5 min. For cotreatment experiment, E~4~ (10^−6^ M) or vehicle (DMSO) was pre-incubated during 10 min prior to E~2~ (10^−8^ M) treatment. The concentration of NO gas in the tissue was measured in real time with the data acquisition system LabTrax (WPI) connected to the free radical analyzer Apollo1000 (WPI). Data acquisition and analysis were performed with DataTrax2 software (WPI). The NO-specific amperometric probe was calibrated as previously described (Knauf *et al*, [@b27]).

Proximity Ligation Assay
------------------------

The Proximity Ligation Assay (PLA) technology was developed by Olink Bioscience (Sweden) (Soderberg *et al*, [@b42]) and is commercialized by Sigma-Aldrich. For PLA, MCF-7 cells (5 × 10^4^ cells/ml) were grown on coverslips into 24-well plates in phenol red-free DMEM/F12 containing 5% charcoal-stripped FCS and were treated or not with E~2~ (10 nM) or E~4~ (1 μM) for 5 min. Cells were then fixed in 4% paraformaldehyde for 10 min and washed in large amount of PBS, and the coverslips were treated according to manufacturer\'s instructions (Duolink II Fluorescence, Olink Bioscience). Then, couple of primary antibodies rabbit anti-ERα (HC20 (Santa Cruz technology) and mouse anti-Src (B12, Santa Cruz Technology) was incubated overnight at 4°C in PBS with 0.2% triton and 0.5% non-fat milk. After washes, the PLA minus and plus probes (containing the secondary antibodies conjugated with complementary oligonucleotides) were added and incubated 1 h at 37°C. The next step allows the ligation of oligonucleotides if the two proteins are in close proximity thanks to the ligase during an incubation of 30 min at 37°C. After washes, the addition of nucleotides and polymerase allows amplification by rolling-circle amplification reaction using the ligated circle as a template during an incubation of 100 min at 37°C. The amplification solution also contains fluorescently labeled oligonucleotides that hybridize to the rolling-circle amplification product. The coverslips were let drying at room temperature in the dark and were mounted with Duolink II mounting Medium containing Dapi. The hybridized fluorescent slides were viewed under a Zeiss AxioImager Z1 microscope. Images were acquired under identical conditions at objective ×40. On each samples, at least 500 cells were counted. Analyses and quantifications of these samples were performed using ImageJ software that allows counting dots on 8 bits image and the plugin 'Counter cells' allows analyzing cells number.

### The paper explained

#### Problem

Estetrol (E~4~) is an estrogen produced by the human fetal liver only during pregnancy. A recent clinical phase II study evaluating its contraceptive properties revealed that E~4~ did not change the levels of hepatic-derived proteins, including coagulation factors. Thus, at variance to classically used estrogens, it might not increase thrombo-embolic events. The molecular mechanism of action of E~4~ is essentially unknown, and the goal of this study was to define the nuclear/transcriptional actions versus the membrane/rapid actions in comparison to E~2~.

#### Results

In this study, we show that E~4~ is less potent than E~2~ to activate estrogen receptor alpha (ERα), but a high dose is able to modulate the transcriptional activity of ERα in the uterus, the proliferation of endometrial epithelium and to prevent atheroma. In contrast, E~4~ was not only devoid of effects on endothelial healing and eNOS activation, but it antagonized these E~2~ effects that are purely membrane ERα-dependent.

#### Impact

Thus, E~4~ appears not only as less potent estrogen than E~2~ but behaves as a natural selective ER modulator, and its spectrum of action as safe oral contraceptive or hormonal treatment of menopause should now be considered.

Statistical analyses
--------------------

Results are expressed as the mean ± SEM (Standard Error Mean). To test the effect of treatments, 1-way ANOVA was performed. To test the respective roles of treatment and genotype (ERα deficiency), a 2-way ANOVA was performed. When an interaction was observed between the two factors, the effect of treatment was studied in each genotype using a Bonferroni\'s *post hoc* test. A value of *P *\< 0.05 was considered as statistically significant.
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